RCT | Low-dose Decitabine vs. low-dose Azacitidine in lower-risk myelodysplastic syndromes.
11 Aug, 2022 | 12:04h | UTCLow-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence
Commentary on Twitter
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. https://t.co/OSpNLzfiKW#MDS #LeuSM #CMML pic.twitter.com/BN1XAhfUBo
— NEJM Evidence (@NEJMEvidence) August 9, 2022